These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8352267)

  • 1. Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration.
    Besarab A
    Am J Kidney Dis; 1993 Aug; 22(2 Suppl 1):13-22. PubMed ID: 8352267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.
    Besarab A; Flaharty KK; Erslev AJ; McCrea JB; Vlasses PH; Medina F; Caro J; Morris E
    J Am Soc Nephrol; 1992 Mar; 2(9):1405-16. PubMed ID: 1627763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.
    Paganini EP; Eschbach JW; Lazarus JM; Van Stone JC; Gimenez LF; Graber SE; Egrie JC; Okamoto DM; Goodkin DA
    Am J Kidney Dis; 1995 Aug; 26(2):331-40. PubMed ID: 7645538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
    Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
    Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
    JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis.
    Ongkingco JR; Ruley EJ; Turner ME; Fragale MR
    Am J Nephrol; 1994; 14(1):14-8. PubMed ID: 8017476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
    Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group.
    Levin NW; Lazarus JM; Nissenson AR
    Am J Kidney Dis; 1993 Aug; 22(2 Suppl 1):3-12. PubMed ID: 8352269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group.
    Weiss LG; Clyne N; Divino Fihlho J; Frisenette-Fich C; Kurkus J; Svensson B
    Nephrol Dial Transplant; 2000 Dec; 15(12):2014-9. PubMed ID: 11096148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
    N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of epoetin dose on hematocrit.
    Cotter D; Zhang Y; Thamer M; Kaufman J; Hernán MA
    Kidney Int; 2008 Feb; 73(3):347-53. PubMed ID: 18004296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of once-weekly epoetin alfa.
    Barre P; Reichel H; Suranyi MG; Barth C
    Clin Nephrol; 2004 Dec; 62(6):440-8. PubMed ID: 15630903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A decision analysis comparing three dosage regimens of subcutaneous epoetin in continuous ambulatory peritoneal dialysis.
    Piccoli A; Puggia RM; Fusaro M; Favaro E; Pillon L
    Pharmacoeconomics; 1995 May; 7(5):444-56. PubMed ID: 10155331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients.
    Parker KP; Sands JM
    J Am Soc Nephrol; 1993 Apr; 3(10):1717-8. PubMed ID: 8318688
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous.
    Hörl WH
    Acta Haematol; 1992; 87 Suppl 1():16-9. PubMed ID: 1574961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly subcutaneous recombinant human erythropoietin corrects anemia of progressive renal failure.
    Zappacosta AR; Perras ST; Bell A
    Am J Med; 1991 Sep; 91(3):229-32. PubMed ID: 1892142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD.
    Saleh A; Krane NK; Caballero M; Starks E
    Adv Perit Dial; 1991; 7():288-91. PubMed ID: 1680448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.